Shubham Pant, Professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at MD Anderson Cancer Center, shared on LinkedIn:
” ‘My patient is starting Daraxonrasib, Rasonque. What should I watch for, and how do I manage the side effects?’
Over the past several months, I’ve heard some version of this repeatedly in emails, texts, and hallway questions from colleagues across the country and around the world.
It’s a great question, and it shows how quickly RAS-targeted therapy is moving from trials into real-world practice. But answering one email at a time wouldn’t cut it.
So, my colleague Tanios Bekaii-Saab and I, along with Open Medicine, put together a simple, practical algorithm for managing Daraxonrasib side effects: what to look for, when to intervene, and how to keep patients on therapy safely.
The goal is to make this information easy to find and easy to use, whether you’re at a major cancer center, a community practice, or anywhere in the world.
This is a living document. As more data on side effects emerges, we’ll keep updating it.
Link: Please share it with anyone caring for patients on this therapy.
Disclaimer: This algorithm is meant as a practical guide, not a substitute for clinical judgment. Every patient is different, so please tailor management to the individual in front of you.”
Shubham Pant: RAS Takes Center Stage at the Fourth Global Summit on GI Malignancies
